BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » MSCs

What is Cord Tissue Banking?

December 28, 2021 By Cade Hildreth (CEO) Leave a Comment

Cord tissue banking is the processing and storage of a newborn’s umbilical cord tissue or the components contains, such as Wharton’s jelly. Wharton’s jelly is a thick, gelatinous substance present within the human umbilical cord that contains a range of important cell types, such as mesenchymal stem cells (MSCs), fibroblasts and macrophages.

In this article:

  • Definition of Cord Tissue Banking
  • History of Cord Tissue Banking
  • Cord Tissue Banking in U.S.

[Read more…]

Filed Under: Cell Therapy, Cord Blood Tagged With: cord blood, cord tissue, MSCs

Commence Bio Receives 1st Patent for MSC1, An Innovative Cancer Immunotherapy Platform

June 22, 2016 By Cade Hildreth (CEO) Leave a Comment

Commence Bio Receives 1st Patent for MSC1, An Innovative Cancer Immunotherapy Platform

In major news released this week, Commence Bio announced that the company has received its first patent for MSC1. Commence Bio is a pre-clinical stage biotechnology company that is based on the concept that cancer and other inflammatory conditions can be addressed by “rebooting patients’ immune systems” with a new class of medicinal stem cells, MSC1 and MSC2.

The company is now developing a therapeutic pipeline, as well as offering research products that include MSC1 and MSC2 cells and media. The concept around which the company is based is that its proprietary “stimulated Toll-like receptor technology” programs naïve MSCs to either a more potent anti-inflammatory phenotype, or a new pro-inflammatory, anti-tumor phenotype. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: cancer, Commence Bio, MSCs

Market Brief – Opportunities and Threats within the Cord Blood Banking Industry

April 18, 2016 By Cade Hildreth (CEO) 1 Comment

Brief: Opportunities and Threats within the Cord Blood Banking Industry - Depositphotos_3306438_m-2015-e1460995483660.jpg

The cord blood banking industry is a complex industry, with numerous benchmarks that indicate the overall health of the industry, including public and private storage of cord blood and cord tissue units, utilization rates for cord blood, regional and global rates of hematopoietic stem cell transplantation (HSCT), and more.

Benchmarks are critical to assess, because the global cord blood market has matured substantially over the past few years, creating both serious threats and novel opportunities. Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.

Serious threats to the cord blood industry include:
[Read more…]

Filed Under: Cord Blood, Stem Cells Tagged With: cord blood, cord blood banking industry, HSCs, MSCs, stem cell therapy

Cynata Partners with Harvard University and University of Sydney

November 11, 2015 By Cade Hildreth (CEO) Leave a Comment

Investors are Paying Attention: Cynata Partnerships and Activity Report

In a recent “Activity Report” released by Cynata Therapeutics, the company announced the status of key business activities and partnerships, including a recent collaboration with Harvard Medical School to treat cancer using toxin-secreting stem cells. It has also entered into a collaboration with the University of Sydney that will address myocardial infarction using the therapeutic properties Cynata’s iPSC-derived mesenchymal stem cells (MSCs).

In addition, the company recently announced that their Cymerus™ derived MSCs will be utilized in a clinical trial for GvHD, the first in-patient test of the company’s novel stem cell manufacturing process.

These activities are resulting from Cynata’s proprietary manufacturing platform that can produce unlimited quantities of mesenchymal stem cells (MSCs) by deriving them from induced pluripotent stem cells (iPSCs) produced from a single donor. This Cymerus™ technology has made Cynata one of the first commercial providers to achieve consistent, scalable, and importantly, cost-effective production of clinical-grade stem cells. The company’s novel manufacturing approach is overcoming a major hurdle that has traditionally limited the therapeutic use of stem cells, which is the “sky high costs” associated with such procedures.  [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: cancer, Cymerus, cynata therapeutics, Harvard, mesenchymal stem cells, MSCs, myocardial infarction, University of Sydney

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.